

AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions, and listings, of claims in the application:

1-47. (Cancelled).

48. (Currently amended) A packaged pharmaceutical composition comprising:


(a) a pharmaceutical composition comprising:

(i) a compound of the formula:



or a pharmaceutically acceptable salt thereof wherein:

Q represents a group of the Formula:



wherein A is C₁-C₅ alkylene optionally mono-, di, or trisubstituted with substituents independently chosen from C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, halo(C₁-C₃)alkyl, halo(C₁-C₃)alkoxy, hydroxy, amino, and mono- or di(C₁-C₃)alkylamino;

R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈ are the same or different and independently represent hydrogen, halogen, cyano, nitro, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, hydroxy, amino, mono or di(C₁-C₆)alkyl amino, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, C₁-C₆ alkanoyl, C₁-C₆ alkoxycarbonyl, -COOH, -SO₂NH₂, mono or dialkylsulfonamido, -C(O)NH₂, or mono or di(C₁-C₆)alkylcarboxamido;

R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, and R₁₉ independently represent hydrogen or C₁-C₆ alkyl;

W is nitrogen or C-R_a where R_a represents hydrogen, hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkyl or cyano;

X represents halogen, cyano, nitro, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, hydroxy, amino, mono or di(C₁-C₆)alkylamino, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, C₁-C₆ alkanoyl, C₁-C₆ alkoxycarbonyl, -COOH, -CONH₂, mono- or di(C₁-C₆)alkylcarboxamido, -SO₂NH₂, mono or di(C₁-C₆)alkylsulfonamido; or

X represents phenyl which may be optionally substituted by up to five substituents, which may be the same or different and are selected from the group consisting of hydrogen, halogen, cyano, nitro, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, hydroxy, amino, mono or di(C₁-C₆)alkyl amino, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, C₁-C₆ alkanoyl, C₁-C₆ alkoxycarbonyl, -COOH, -CONH₂, mono- or di-(C₁-C₆)alkylcarboxamido, -SO₂NH₂, and mono or di(C₁-C₆)alkylsulfonamido;

Y is oxygen, sulfur, -S(O)-, or -SO₂-; and

Z is C₁-C₆ alkyl or mono, di or trifluoromethyl; and


(ii) at least one pharmaceutically acceptable carrier or excipient; and

(b) instructions for using the composition to treat a patient suffering from an eating disorder or sexual disorder obesity.

49-53. (Cancelled)

54. (Currently amended) A packaged pharmaceutical composition according to claim 48, wherein the instructions are provided as labeling ~~on~~ and the package includes a container holding the compound or the pharmaceutically acceptable salt thereof and the at least one pharmaceutically acceptable carrier or excipient.

55. (Previously presented) A packaged pharmaceutical composition according to claim 48, wherein Q is a group of the Formula:



and A is methylene optionally substituted with C₁-C₂ alkyl.

56. (Previously presented) A packaged pharmaceutical composition according to claim 55, wherein A is methylene and W is nitrogen.

57. (Previously presented) A packaged pharmaceutical composition according to claim 56, wherein R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈ and R₁₉ are hydrogen.

58. (Previously presented) A packaged pharmaceutical composition according to claim 57, wherein:

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl or trifluoromethoxy;

X is halogen or phenyl;

Y is oxygen; and

Z is C₁-C₆ alkyl.

59. (Previously presented) A packaged pharmaceutical composition according to claim 55, wherein A is methylene and W is CH.

60. (Previously presented) A packaged pharmaceutical composition according to claim 59, wherein R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈ and R₁₉ are hydrogen.

61. (Previously presented) A packaged pharmaceutical composition according to claim 60, wherein:


R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl or trifluoromethoxy;

X is halogen or phenyl;

Y is oxygen; and


Z is C₁-C₆ alkyl.

62. (Previously presented) A packaged pharmaceutical composition according to claim 48, wherein the compound has the formula:



wherein A is methylene optionally substituted with C₁-C₂ alkyl.

63. (Previously presented) A packaged pharmaceutical composition according to claim 48, wherein the compound has the formula:



64. (Previously presented) A packaged pharmaceutical composition according to claim 63, wherein

R₁₃, R₁₅, R₁₇ and R₁₉ are hydrogen;

R₁₀, R₁₁, R₁₂, R₁₄, R₁₆ and R₁₈ independently represent hydrogen or methyl;

W is N or CH;

R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈ independently represent hydrogen, halogen, C₁-C₆ alkyl,


C₁-C₆ alkoxy, trifluoromethyl or trifluoromethoxy;

X is hydrogen or halogen;

Y is oxygen; and

Z is C₁-C₆ alkyl.

65. (Previously presented) A packaged pharmaceutical composition according to claim 48, wherein the compound has the formula:



66. (Previously presented) A packaged pharmaceutical composition according to claim 65, wherein

R₁₃, R₁₅, R₁₇ and R₁₉ are hydrogen;

R₁₀, R₁₁, R₁₂, R₁₄, R₁₆ and R₁₈ independently represent hydrogen or methyl;

W is N or CH;

R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈ independently represent hydrogen, halogen, C₁-C₆ alkyl,

C₁-C₆ alkoxy, trifluoromethyl or trifluoromethoxy;

X is hydrogen or halogen;

Y is oxygen; and

Z is C₁-C₆ alkyl.

67. (Previously presented) A packaged pharmaceutical composition according to claim 48, wherein the compound is selected from:

1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

(1*S*, 2*S*)-1-(4-bromo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl)methylpiperazine;

1*R*, 2*R*-1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

1-(4-Iodo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

1-(4-Chloro-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

1-(4-Phenyl-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

1-(4-Bromo-3-methoxyphenyl)-4-[*trans*-2-(3-methoxyphenyl)cyclopropyl] methylpiperazine;

1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-[4-chlorophenyl] cyclopropyl)
 methylpiperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-[2-methylphenyl]
 cyclopropyl)methylpiperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-[4-methoxyphenyl]
 cyclopropyl)methylpiperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Iodo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Chloro-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Methyl-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Trifluoromethyl-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl)
 methylpiperidine;
 1-(4-Bromo-3-ethoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-phenyl]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2-methylphenyl}]propen-2-yl)piperazine;
 1-(3-Methoxyphenyl)-4-([3-phenyl]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{3-methylphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2-methoxyphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{3-chlorophenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{3-ethoxyphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2,3-dimethoxyphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{3,4-dimethoxyphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2,5-dimethoxyphenyl}]propen-2-yl)piperazine;
 and
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2,4-dimethoxyphenyl}]propen-2-yl)piperazine.